文献速递药物相互作用特殊人群用药药物不良反应与药物警戒

Polmacoxib(CG100649)的临床药代动力学:一种组织选择性COX-2与碳酸酐酶I/II双重抑制剂

Clinical Pharmacokinetics of Polmacoxib (CG100649): A Tissue-Selective Dual COX-2 and Carbonic Anhydrase I/II Inhibitor.
PubMed 文献 · Clin Pharmacokinet · 2026-10-15

本综述系统检索PubMed、Embase等数据库至2026年6月,总结Polmacoxib的临床药代动力学与PK-PD特征。Polmacoxib通过高亲和力结合碳酸酐酶I/II被红细胞隔离,全血浓度约为血浆的50-78倍,终末半衰期在血液中约121-203小时。2mg每日一次对WOMAC疼痛终点非劣于塞来昔布200mg。

要点

  • Polmacoxib全血浓度平均为血浆的50-78倍,个体值可达120倍,终末半衰期血液约121-203小时。
  • 酮康唑仅引起血浆暴露的适度变化,提示DDI风险有限。
  • 2mg每日一次在WOMAC疼痛终点非劣于塞来昔布200mg。

核心结论

  • Polmacoxib具有区别于其他昔布类的独特PK特征,由红细胞碳酸酐酶结合驱动,支持其组织选择性药理学假说。

研究设计与样本

  • 本综述检索PubMed、Embase、Scopus、Web of Science、Google Scholar和ClinicalTrials.gov至2026年6月,并补充参考文献列表及监管、专利和Protein Data Bank记录。

主要发现

  • 口服给药后全血浓度平均约为血浆浓度的50-78倍,个体值接近120倍。
  • 终末半衰期在血液中约为121-203小时,在血浆中约为100-167小时。
  • 二室全血模型联合零级和一级混合吸收最好地描述数据,血清铁、白细胞计数和年龄被确定为清除率的协变量。
  • 2mg每日一次显著抑制血栓素B2和离体PGE2,对尿前列环素代谢物(PGI-M)仅呈适度、剂量依赖性抑制,单次给药后抑制幅度与塞来昔布200mg相当但持续时间较短。
  • 2mg剂量在骨关节炎WOMAC疼痛终点上非劣于塞来昔布200mg。

关键数值与推荐

  • 2mg每日一次为已批准的骨关节炎剂量,在WOMAC疼痛终点非劣于塞来昔布200mg。
  • 酮康唑仅引起血浆暴露的适度变化。
  • 肝损伤、肾损伤、老年人和非韩国人群的PK数据仍有限。

临床怎么用

  • 临床用药时应关注Polmacoxib独特的红细胞隔离特征导致的全血浓度远高于血浆浓度。
  • 在肝损伤、肾损伤、老年人和非韩国人群中处方时应谨慎,因PK数据有限。
  • 与酮康唑合用时无需大幅调整剂量,但仍需监测。

局限性

  • 肝损伤、肾损伤、老年人和非韩国人群的PK数据有限。
  • 需要特殊人群、药物相互作用和上市后研究以支持更广泛的全球使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Polmacoxib (CG100649; Acelex) is a first-in-class non-steroidal anti-inflammatory drug that combines selective cyclooxygenase-2 (COX-2) inhibition with high-affinity binding to carbonic anhydrase I/II (CA-I/II). Approved for osteoarthritis in South Korea (2015) and India (2023), it exhibits pharmacokinetic (PK) properties distinct from other coxibs. The objective of this review is to review the clinical PK and pharmacokinetic-pharmacodynamic (PK-PD) profile of polmacoxib, compare it with other coxibs, and identify key evidence gaps. PubMed, Embase, Scopus, Web of Science, Google Scholar, and ClinicalTrials.gov were searched through June 2026, supplemented by reference lists and regulatory, patent, and Protein Data Bank records. The clinical PK profile of polmacoxib is dominated by erythrocyte sequestration via high-affinity binding to CA-I/II. After oral dosing, whole-blood concentrations exceed plasma concentrations by approximately 50-78 on average, with individual values approaching 120-fold, and terminal half-lives are approximately 121-203 h in blood and 100-167 h in plasma. A 2-compartment whole-blood model with mixed zero- and first-order absorption best describes the data, with serum iron, white-cell count, and age identified as covariates of clearance. The 2-mg once-daily dose substantially inhibits thromboxane B2 and ex vivo PGE2, with only modest, dose-dependent inhibition of urinary prostacyclin metabolite (PGI-M) that is of comparable magnitude, although less sustained, to celecoxib 200 mg after single dosing; the 2-mg dose is noninferior to celecoxib 200 mg on WOMAC pain endpoints in osteoarthritis. Ketoconazole produces only modest changes in plasma exposure, and PK data in hepatic impairment, renal impairment, older people, and non-Korean populations remain limited. Polmacoxib has a unique PK profile among coxibs, driven by erythrocyte carbonic anhydrase binding, which supports its proposed tissue-selective pharmacology. Further studies in special populations, drug-drug interactions, and post-marketing settings are needed to support broader global use.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Mallillin MC, Rashid MH, Abouelbaqa Y, et al. Clinical Pharmacokinetics of Polmacoxib (CG100649): A Tissue-Selective Dual COX-2 and Carbonic Anhydrase I/II Inhibitor. Clin Pharmacokinet. 2026. PMID: 42879101. doi:10.1007/s40262-026-01715-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。